While patients with ER+ tumors have lower recurrence rates within the first five years compared to other subtypes, their risk persists over decades, with >50% of recurrences occurring after five years, and are responsible for the majority of breast-cancer related deaths [9,10]. This evidence concerns the gene ESR1 and breast carcinoma.